Cemiplimab (anti-PD-1)

目录号:A2022 别名: Libtayo, REGN-2810, cemiplimab-rwlc 中文名称:西米普利单抗

For research use only.
Not for use in humans.

Cemiplimab (anti-PD-1) (Libtayo, REGN-2810, cemiplimab-rwlc) 是一种应用于静脉注射的人单克隆抗体,针对 programmed cell death-1 receptor (PD-1) 并阻断其与程序性死亡配体 PD-1 和 PD-L2 的相互作用。Cemiplimab 可阻断 T 细胞失活并增强免疫系统的抗肿瘤反应。

规格 价格 库存 购买数量  
RMB 5790.65 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

质量管理及产品安全说明书

PD-1/PD-L1抑制剂选择性比较

生物活性

产品描述 Cemiplimab (anti-PD-1) (Libtayo, REGN-2810, cemiplimab-rwlc) 是一种应用于静脉注射的人单克隆抗体,针对 programmed cell death-1 receptor (PD-1) 并阻断其与程序性死亡配体 PD-1 和 PD-L2 的相互作用。Cemiplimab 可阻断 T 细胞失活并增强免疫系统的抗肿瘤反应。
体外研究

In cell-based assays, REGN2810 reverses PD-1-dependent attenuation of T-cell receptor signaling in engineered T cells and enhances responses of human primary T cells.[1]

体内研究

Cemiplimab (REGN2810) binds the humanized PD-1 receptor and inhibits growth of MC38 murine tumors in human PD-1 knock-in mice. As REGN2810 binds to cynomolgus monkey PD-1 with high affinity, pharmacokinetic and toxicologic assessment of REGN2810 is performed in cynomolgus monkeys. High doses of REGN2810 are well tolerated, without adverse immune-related effects.[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:
- 合并
  • Objective: T cell activation bioassays
    Cells: Jurkat/AP-1-Luc/hPD-1 cells, HEK293/hCD20 cells, HEK293/hCD20/hPD-L1 cells
    Concentrations: 0.1 pM-0.1 μM
    Incubation Time: 4-6 h
    Method: Antigenpresenting cell (APC)-like HEK293 cells are generated by lentiviral transduction of human CD20 and human PD-L1. T-cell receptor (TCR) activation is achieved by an antiCD3 x anti-CD20 bispecific antibody. To generate a dose response curve for anti-CD3 x anti-CD20, the bispecific molecule is serially diluted and tested with 50,000/well Jurkat/AP-1-Luc/hPD-1 and 10,000/well HEK293/hCD20 or HEK293/hCD20/hPD-L1 cells in a 96-well plate. Serially diluted REGN2810 is tested under similar conditions in the presence of a fixed concentration of anti-CD3 x anti-CD20 (100 pM). Plates are incubated at 37°C for 4-6 hours.
    Reference: https://pubmed.ncbi.nlm.nih.gov/28265006/

    Objective: T cell activation bioassays
    Cells: HEK293/hCD20/hPD-L1 cells, CD4+ T cells, HEK293/hCD20/hPD-L1 cells
    Concentrations: 0.1 pM-0.1 μM
    Incubation Time: 72 h
    Method: HEK293/hCD20/hPD-L1 cells are treated with 50 mg/mL mitomycin C for 30 minutes at 37°C to inhibit proliferation. Serially diluted REGN2810 is incubated with 50,000/well preactivated CD4+ T cells and 25,000/well of HEK293/hCD20/hPD-L1 cells in the presence of 2 nM anti-CD3 x anti-CD20 bispecific antibody in a 96-well plate for 72 hours.
    Reference: https://pubmed.ncbi.nlm.nih.gov/28265006/

    Cemiplimab can apply to nude mice, various cancer cell lines and other related assays (Only for Reference)

动物实验:
- 合并
  • Objective: MC38 mouse colon carcinoma
    Animal Models: adult human PD-1 knock-in mice
    Formulation: --
    Dosages: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg
    Administration: i.p.
    Reference: https://pubmed.ncbi.nlm.nih.gov/28265006

    Objective: pharmacokinetic (PK) study
    Animal Models: cynomolgus monkeys (Macaca fascicularis)
    Formulation: --
    Dosages: 1 mg/kg, 5 mg/kg, 15 mg/kg
    Administration: i.v.
    Reference: https://pubmed.ncbi.nlm.nih.gov/28265006

    Cemiplimab can apply to nude mice, various cancer cell lines and other related assays (Only for Reference)

抗体信息

CAS No. 1801342-60-8
配制 PBS buffer. Contains no stabilizers or preservatives
同型 Human IgG4
来源 HEK293
储存条件 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

技术支持

如果有其他问题,请给我们留言。

  • * 必填项
Tags: 购买Cemiplimab (anti-PD-1) | Cemiplimab (anti-PD-1)供应商 | 采购Cemiplimab (anti-PD-1) | Cemiplimab (anti-PD-1)价格 | Cemiplimab (anti-PD-1)生产 | 订购Cemiplimab (anti-PD-1) | Cemiplimab (anti-PD-1)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID